BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38695532)

  • 1. Genetically Edited Cascade Nanozymes for Cancer Immunotherapy.
    Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
    ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A homologous-targeting cGAS-STING agonist multimodally activates dendritic cells for enhanced cancer immunotherapy.
    Wang P; Wang Y; Li H; Wang M; Wang Y; Wang X; Ran L; Xin H; Ma J; Tian G; Gao W; Zhang G
    Acta Biomater; 2024 Mar; 177():400-413. PubMed ID: 38336268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metal coordination nanotheranostics mediated by nucleoside metabolic inhibitors potentiate STING pathway activation for cancer metalloimmunotherapy.
    Yang L; Wang Y; Song Y; Li Z; Lei L; Li H; He B; Cao J; Gao H
    J Control Release; 2024 Jun; 370():354-366. PubMed ID: 38685387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-derived nanovesicles enhance cancer synergistic chemo-immunotherapy by promoting cGAS/STING pathway activation and immunogenetic cell death.
    Guo Y; Qian R; Li Z; Lv T; Yang C; Li W; Pan T; Hou X; Wang Z
    Life Sci; 2024 Jul; 348():122687. PubMed ID: 38718856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A manganese-phenolic network platform amplifying STING activation to potentiate MRI guided cancer chemo-/chemodynamic/immune therapy.
    Pang X; Fu C; Chen J; Su M; Wei R; Wang Y; Lin W; Wei X; Jiang X; Yang X; Yang H; Wang J; Yang R
    Biomater Sci; 2023 May; 11(11):3840-3850. PubMed ID: 37074080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
    Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
    Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers.
    Yi M; Niu M; Zhang J; Li S; Zhu S; Yan Y; Li N; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2021 Sep; 14(1):146. PubMed ID: 34526097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outer membrane vesicle-wrapped manganese nanoreactor for augmenting cancer metalloimmunotherapy through hypoxia attenuation and immune stimulation.
    Luo S; Yang Y; Chen L; Kannan PR; Yang W; Zhang Y; Zhao R; Liu X; Li Y; Kong X
    Acta Biomater; 2024 Jun; 181():402-414. PubMed ID: 38734282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential reinforcement of cGAS-STING pathway-involved immunotherapy by biomineralized bacterial outer membrane-sensitized EBRT and RNT.
    Shen M; Guo L; Zhang H; Zheng B; Liu X; Gu J; Yang T; Sun C; Yi X
    J Nanobiotechnology; 2024 Jun; 22(1):310. PubMed ID: 38831378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Microenvironment-Activable Manganese-Boosted Catalytic Immunotherapy Combined with PD-1 Checkpoint Blockade.
    Zhao Z; Dong S; Liu Y; Wang J; Ba L; Zhang C; Cao X; Wu C; Yang P
    ACS Nano; 2022 Dec; 16(12):20400-20418. PubMed ID: 36441901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
    Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomineralized MnO
    Deng Z; Xi M; Zhang C; Wu X; Li Q; Wang C; Fang H; Sun G; Zhang Y; Yang G; Liu Z
    ACS Nano; 2023 Mar; 17(5):4495-4506. PubMed ID: 36848115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmenting Immunotherapy via Bioinspired MOF-Based ROS Homeostasis Disruptor with Nanozyme-Cascade Reaction.
    Wang R; Qiu M; Zhang L; Sui M; Xiao L; Yu Q; Ye C; Chen S; Zhou X
    Adv Mater; 2023 Dec; 35(49):e2306748. PubMed ID: 37689996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reinforcing the Induction of Immunogenic Cell Death Via Artificial Engineered Cascade Bioreactor-Enhanced Chemo-Immunotherapy for Optimizing Cancer Immunotherapy.
    Sun K; Hu J; Meng X; Lei Y; Zhang X; Lu Z; Zhang L; Wang Z
    Small; 2021 Sep; 17(37):e2101897. PubMed ID: 34363310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal.
    Wang Z; Chen L; Ma Y; Li X; Hu A; Wang H; Wang W; Li X; Tian B; Dong J
    J Nanobiotechnology; 2021 Aug; 19(1):243. PubMed ID: 34384429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
    Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
    Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.